MB-103 is under clinical development by Mustang Bio and currently in Phase I for Brain Cancer. According to GlobalData, Phase I drugs for Brain Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MB-103 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-103 overview
MB-103 is under development for the treatment of glioblastoma multiforme, breast cancer patients with brain metastases and leptomeningeal metastasis brain cancer. The drug candidate consists of lentivirally transduced chimeric antigen receptor (CAR-T) cells that target tumour cells expressing receptor tyrosine protein kinase (HER2). The drug candidate is administered through intraventricular route. It is developed based on human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 technology).
See Also:
Mustang Bio overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
For a complete picture of MB-103’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
